BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10605307)

  • 21. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
    Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
    Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
    Leonardo C; Simone G; Papalia R; Franco G; Guaglianone S; Gallucci M
    Int J Urol; 2009 Jun; 16(6):584-6. PubMed ID: 19453762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
    Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
    BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Screening of cancer of the prostate (IV). Economic approach: the costs of screening tests and treatment. Members of the Sub-Committee of the Prostate of CCAFU].
    Haillot O; Villers A; Soulie M; Baron JC
    Prog Urol; 1998 Sep; 8(4):517-23. PubMed ID: 9834514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0.
    Tilly W; Gellermann J; Graf R; Hildebrandt B; Weissbach L; Budach V; Felix R; Wust P
    Strahlenther Onkol; 2005 Jan; 181(1):35-41. PubMed ID: 15660191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in treatment costs for localized prostate cancer: the healthy screenee effect.
    Zeliadt SB; Etzioni R; Ramsey SD; Penson DF; Potosky AL
    Med Care; 2007 Feb; 45(2):154-9. PubMed ID: 17224778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
    Dudderidge T; Payne H; Emberton M
    BJU Int; 2007 Sep; 100(3):518-27. PubMed ID: 17573894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report.
    Sasaki T; Nakamura K; Shioyama Y; Ohga S; Urashima Y; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Honda H
    Jpn J Clin Oncol; 2004 Jul; 34(7):420-4. PubMed ID: 15342670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
    Brandeis J; Pashos CL; Henning JM; Litwin MS
    Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenocarcinoma of the prostate: an expensive way to die.
    Piper NY; Kusada L; Lance R; Foley J; Moul J; Seay T
    Prostate Cancer Prostatic Dis; 2002; 5(2):164-6. PubMed ID: 12497008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
    Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.